Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market
This article was originally published in The Tan Sheet
Executive Summary
Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.
You may also be interested in...
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.
PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk